These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 35346850)
1. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status. Lymberopoulos P; Shaikh A; Rich NE; Benhammou JN; Kanwal F; Cholankeril G Clin Gastroenterol Hepatol; 2023 May; 21(5):1362-1364.e1. PubMed ID: 35346850 [TBL] [Abstract][Full Text] [Related]
2. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Bohorquez H; Bugeaud E; Bzowej N; Scheuermann J; Hand J; Bruce D; Carmody I; Cohen A; Joshi S; Seal J; Sonnier D; Therapondos G; Girgrah N; Anders S; Loss GE Liver Transpl; 2021 Apr; 27(4):548-557. PubMed ID: 33098277 [TBL] [Abstract][Full Text] [Related]
3. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Shaikh A; Goli K; Lee TH; Rich NE; Benhammou JN; Keeling S; Kim D; Ahmed A; Goss J; Rana A; Singal AG; Kanwal F; Cholankeril G Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2288-2297.e4. PubMed ID: 36521738 [TBL] [Abstract][Full Text] [Related]
4. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers. Mazur RD; Goldberg DS Liver Transpl; 2019 Dec; 25(12):1800-1810. PubMed ID: 31539195 [TBL] [Abstract][Full Text] [Related]
5. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517 [TBL] [Abstract][Full Text] [Related]
6. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. Young K; Liu B; Bhuket T; Gish RG; Wong RJ J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of kidney, liver, and simultaneous liver and kidney transplants from hepatitis c infected donors to hepatitis c naïve recipients: A large single center experience. Elbeshbeshy H; Modi N; Patel T; Matthews I; Kampert T; Lee J; Okeke R; Caliskan Y; Fleetwood V; Varma C; Gabris B; Bastani B; Abu Al Rub F; Guenette A; Befeler A; Agbim U; Desai R; Alsabbagh E; Qureshi K; Schnitzler M; Lentine KL; Randall HB; Nazzal M Clin Transplant; 2024 Jan; 38(1):e15161. PubMed ID: 37842872 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience. Kapila N; Menon KVN; Al-Khalloufi K; Vanatta JM; Murgas C; Reino D; Ebaid S; Shaw JJ; Agrawal N; Rhazouani S; Navas V; Sheffield C; Rahman AU; Castillo M; Lindenmeyer CC; Miller C; Quintini C; Zervos XB Hepatology; 2020 Jul; 72(1):32-41. PubMed ID: 31659775 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Singal AK; Satapathy SK; Reau N; Wong R; Kuo YF Dig Liver Dis; 2020 Jan; 52(1):98-101. PubMed ID: 31582326 [TBL] [Abstract][Full Text] [Related]
10. Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era. Okumura K; Sogawa H; Samson D; Butler J; Veillette G; John D; Diflo T; Bodin R; Wolf DC; Latifi R; Nishida S Transplant Proc; 2022 Sep; 54(7):1834-1838. PubMed ID: 35933231 [TBL] [Abstract][Full Text] [Related]
11. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study. Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110 [TBL] [Abstract][Full Text] [Related]
12. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903 [TBL] [Abstract][Full Text] [Related]
13. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence. Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773 [TBL] [Abstract][Full Text] [Related]
14. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. Chen Q; Ayer T; Adee MG; Wang X; Kanwal F; Chhatwal J JAMA Netw Open; 2020 Nov; 3(11):e2021173. PubMed ID: 33206188 [TBL] [Abstract][Full Text] [Related]
15. Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation. Ichikawa T; Nakao K; Hamasaki K; Honda T; Shibata H; Akahoshi M; Eguchi S; Takatsuki M; Kanematsu T; Eguchi K World J Gastroenterol; 2007 Aug; 13(30):4149-51. PubMed ID: 17696240 [TBL] [Abstract][Full Text] [Related]
16. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study. Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of Lung Transplantation From Hepatitis C Viremic Donors. Li SS; Osho A; Moonsamy P; Wolfe S; Villavicencio MA; Langer N; Sundt TM; Funamoto M Ann Thorac Surg; 2022 May; 113(5):1598-1607. PubMed ID: 34062125 [TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Kwong AJ; Wall A; Melcher M; Wang U; Ahmed A; Subramanian A; Kwo PY Am J Transplant; 2019 May; 19(5):1380-1387. PubMed ID: 30378723 [TBL] [Abstract][Full Text] [Related]
19. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era. Kwong AJ; Kim WR; Flemming JA Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886 [TBL] [Abstract][Full Text] [Related]
20. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]